[{"data":1,"prerenderedAt":253},["ShallowReactive",2],{"story-129116-en":3},{"id":4,"slug":5,"slugs":5,"currentSlug":5,"title":6,"subtitle":7,"coverImagesSmall":8,"coverImages":9,"content":50,"questions":51,"relatedArticles":76,"body_color":251,"card_color":252},"129116",null,"FDA Vaccine Leadership Chaos Signals Regulatory Risk for Health Product Sellers","- Second FDA vaccine chief departure in 12 months creates unpredictable approval environment affecting 50K+ health/supplement sellers and biotech suppliers",[],[10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,23,25,26,27,28,29,30,31,32,33,34,35,36,37,35,35,38,39,40,41,42,43,44,35,45,46,47,48,19,49],"https://static.biospace.com/dims4/default/ff515b6/2147483647/strip/true/crop/1730x974+80+0/resize/1000x563!/quality/90/?url=https%3A%2F%2Fstatic.biospace.com%2F45%2Faf%2Fc648411e4dc99839b22b13d4a54c%2Fprasad-fda-direct.png","https://res.cloudinary.com/graham-media-group/image/upload/f_auto/q_auto/c_scale,w_640/v1/media/gmg/W7VRIGAJ2RAAZA7RLIPNVAQLY4.jpg?_a=DAJHqpE+ZAAA","https://cdn.kpbs.org/dims4/default/2b115d7/2147483647/strip/true/crop/1600x985+0+107/resize/880x542!/quality/90/?url=https%3A%2F%2Fnpr.brightspotcdn.com%2Fdims3%2Fdefault%2Fstrip%2Ffalse%2Fcrop%2F1600x1200%200%20111%2Fresize%2F1600x1200%21%2F%3Furl%3Dhttp%3A%2F%2Fnpr-brightspot.s3.amazonaws.com%2F48%2Fc4%2F195253d64a70a73b22515ee9e3e7%2Fap26065834810784.jpg","https://cdn.sanity.io/images/0vv8moc6/contagion/475f2665ba9317463ea8916d4490434dfd223a20-370x438.jpg?w=370&max-h=438&fit=crop&auto=format","https://i.ntd.com/assets/uploads/2026/03/id1130525-Vinay-Prasad.jpg-900x506.webp","https://s.yimg.com/ny/api/res/1.2/M2bAJ.lozvLiFjBkQVZJmQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyNDI7aD04Mjg7Y2Y9d2VicA--/https://media.zenfs.com/en/ap.org/a35884871554f404a4ef9194c7fb8cf1","https://npr.brightspotcdn.com/dims3/default/strip/false/crop/1600x1200+0+111/resize/1100/quality/50/format/jpeg/?url=http%3A%2F%2Fnpr-brightspot.s3.amazonaws.com%2F48%2Fc4%2F195253d64a70a73b22515ee9e3e7%2Fap26065834810784.jpg","https://insights.citeline.com/resizer/v2/CU7KRUVG3JFIZHGBAFAPWI5M6I.jpg?smart=true&auth=7dff26005881f92309e98ff3375b8d19eff93865e982b122df41b7894f453bbc&width=700&height=394","https://s.yimg.com/os/en/bloomberg_holding_pen_162/d2a433f3585a61cf425d00dfd25d9579","https://opinion-images.wsj.net/im-22453064/?size=1.5","https://cdn.benzinga.com/files/images/story/2026/03/07/Silver-Spring--Md--Usa---June-25--2022-T.jpeg?width=1200&height=800&fit=crop","https://dims.apnews.com/dims4/default/9b7b4d8/2147483647/strip/true/crop/5883x3922+0+0/resize/599x399!/quality/90/?url=https%3A%2F%2Fassets.apnews.com%2F6d%2Fe2%2F0561e58f1a6117640a4e583f846d%2Fb376001d2b6441e58125092b33cd15b8","https://assets.medpagetoday.net/media/images/120xxx/120210.jpg?width=0.8","https://kubrick.htvapps.com/htv-prod-media.s3.amazonaws.com/images/ap269ab976bcb22e.jpg?crop=1.00xw:0.847xh;0,0.0240xh&resize=1200:*","https://bloximages.chicago2.vip.townnews.com/wacotrib.com/content/tncms/assets/v3/editorial/9/35/935ed350-85ab-5394-820f-c948d30949cf/69ab5e2e0c230.image.jpg?crop=1763%2C926%2C0%2C124&resize=1200%2C630&order=crop%2Cresize","https://s.hdnux.com/photos/01/63/12/63/30190812/6/ratio3x2_1920.jpg","https://s.abcnews.com/images/Politics/vinay-ht-er-260306_1772840975298_hpMain_16x9_1600.jpg","https://www.rawstory.com/media-library/file-photo-signage-is-seen-outside-of-the-food-and-drug-administration-fda-headquarters-in-white-oak-maryland-u-s-august.jpg?id=61945751&width=980","https://media-cldnry.s-nbcnews.com/image/upload/t_fit-560w,f_auto,q_auto:best/rockcms/2026-03/260306-3x2-Vinay-Prasad-ew-517p-ecab2f.jpg","https://bloximages.chicago2.vip.townnews.com/ottumwacourier.com/content/tncms/assets/v3/editorial/e/96/e9676f8d-4c64-5fb0-a787-12a528e183af/698b7b65bccdc.image.jpg?resize=750%2C500","https://s.yimg.com/os/en/the_hill_articles_341/7afe0fdc7f926fadeb8a3f829dd36194","https://i0.wp.com/tvdelmarva.com/wp/wp-content/uploads/2026/03/news-1772840065444.jpg?resize=1000%2C666&ssl=1","https://img.huffingtonpost.com/asset/69ab68a8150000671601a929.jpeg?cache=8uxrj9JmVU&ops=1778_1000","https://www.washingtonexaminer.com/wp-content/uploads/2026/03/AP25211686437963.jpg?resize=1200,683","https://static.law360news.com/images/law360_square_logo_2021.png","https://hips.hearstapps.com/htv-prod/images/fda-headquarters-jpg-1674492466.jpg?crop=1.00xw%3A1.00xh%3B0%2C0&resize=810%3A*&quality=70","https://bloximages.chicago2.vip.townnews.com/timesargus.com/content/tncms/assets/v3/editorial/3/c3/3c3e2537-665a-5451-bd9c-abf7ddafc7cd/69ab629cae1f1.image.jpg?resize=375%2C500","https://c.firstwordpharma.com/firstwordgroup/assets/adobe/images/fda_signage_building.jpeg","https://images.axios.com/YSIWNSZNFEegwHACNhbMxDeP0Q4=/0x94:5582x3234/1920x1080/2026/03/06/1772835999352.jpg?w=3840","https://images.wral.com/aa627cbf-3780-5473-8d29-d21f1bceadba?w=1200&h=675&f=jpg","https://bloximages.newyork1.vip.townnews.com/newspressnow.com/content/tncms/assets/v3/editorial/7/ca/7cae52d5-505e-5612-b906-9a1c0a479120/698b767d2f906.image.jpg?resize=750%2C500","https://i.guim.co.uk/img/media/be7750f0b599996aa2bf6d4a7688b18d98929079/0_0_5582_3725/master/5582.jpg?width=465&dpr=1&s=none&crop=none","https://sjvsun.com/wp-content/uploads/2021/08/SUNP-Vaccine1.png","https://bloximages.newyork1.vip.townnews.com/thederrick.com/content/tncms/assets/v3/editorial/c/77/c779992d-e053-5d17-8b31-0fc942524db4/698b770198b3c.image.jpg?resize=400%2C267","https://thehill.com/wp-content/uploads/sites/2/2025/08/Prasad-FDA-08.09.png?strip=1","https://www.protectourcare.org/wp-content/uploads/2026/03/PHP-Meta.png","https://static.law360news.com/images/law360_uk_square_logo_2021.png","https://static01.nyt.com/images/2026/03/06/multimedia/06trump-news-header6p2-lphf/06trump-news-header6p2-lphf-articleLarge.jpg?quality=75&auto=webp&disable=upscale","https://img.ksl.com/slc/3147/314732/31473258.JPG?filter=kslv2/responsive_story_lg","https://media.tegna-media.com/assets/AssociatedPress/images/3d93366a-eff0-4932-a021-8b6c4c72446e/20260306T230541/3d93366a-eff0-4932-a021-8b6c4c72446e_750x422.jpg","**FDA regulatory instability is creating significant uncertainty for e-commerce sellers in health, wellness, and supplement categories.** Dr. Vinay Prasad's departure as FDA vaccine chief (effective April 2026) marks the second major leadership change in 12 months, following Dr. Peter Marks' forced resignation in March 2025. This pattern of leadership turnover, combined with contradictory regulatory decisions—including the rejected Moderna flu vaccine application followed by White House-driven reversal—signals deeper institutional instability that directly impacts sellers across multiple e-commerce channels.\n\n**For health product sellers on Amazon, eBay, Shopify, and specialty marketplaces, this regulatory chaos creates three critical operational challenges.** First, approval timelines for health claims and supplement formulations have become unpredictable. Prasad's simultaneous announcements of \"faster drug review processes\" while imposing \"new warnings and study requirements\" created conflicting signals that pharmaceutical suppliers and supplement manufacturers must navigate. Sellers listing health products, vitamins, immune support supplements, and wellness devices face uncertainty about which claims will be permitted, requiring constant monitoring of FDA guidance updates. Second, the pattern of White House pressure on FDA decisions (evidenced by the Moderna vaccine reversal) suggests regulatory decisions may become increasingly politicized rather than science-based, making it difficult for sellers to predict compliance requirements. Third, investor confidence in biotech and health product companies has declined due to unpredictable review standards, potentially affecting supply chain stability and product availability for sellers sourcing from affected manufacturers.\n\n**The broader market impact extends to supplement and wellness categories generating $150B+ annually in US e-commerce.** Sellers in immune support, vitamin D, probiotics, and general wellness categories depend on FDA guidance regarding permissible health claims. The institutional instability at FDA vaccine oversight—the agency's most visible health authority—creates spillover uncertainty affecting all health product categories. Sellers must now budget for potential compliance revisions, claim adjustments, and product reformulations as regulatory direction shifts with leadership changes. The two leadership departures in 12 months suggest this instability will persist through 2026, affecting product development cycles and marketing strategies for the next 18-24 months.",[52,55,58,61,64,67,70,73],{"title":53,"answer":54,"author":5,"avatar":5,"time":5},"Should sellers avoid health product categories due to FDA regulatory risk?","Health and wellness categories remain highly profitable ($150B+ US market) despite regulatory risk. Rather than avoiding these categories, sellers should implement risk management strategies: focus on well-established product types with stable FDA guidance (vitamins, minerals, established supplements); avoid emerging categories with uncertain regulatory status; prioritize third-party testing and clinical substantiation; maintain compliance reserves (5-10% of revenue). Sellers with strong compliance infrastructure can compete effectively. The regulatory uncertainty creates barriers to entry for undercapitalized competitors, potentially benefiting established sellers with compliance resources. Consider this a competitive advantage opportunity rather than a reason to exit.",{"title":56,"answer":57,"author":5,"avatar":5,"time":5},"What marketplace strategies should health sellers adopt during FDA leadership transitions?","During FDA leadership transitions (April-June 2026), health sellers should reduce PPC spending on vaccine-related and immune support products by 15-25% to lower risk exposure. Shift advertising budget toward non-FDA-dependent categories like wellness accessories and fitness equipment. Implement dynamic pricing strategies that account for approval uncertainty—reduce margins by 5-10% on products with pending FDA reviews to accelerate inventory turnover. Monitor competitor inventory levels on Amazon and eBay; if competitors are liquidating health products, it signals market-wide approval concerns. Activate email marketing to existing customers for immune support products before new FDA leadership takes office, as approval timelines may extend post-transition. Consider launching private label products in lower-risk categories to diversify revenue during the 6-month uncertainty window.",{"title":59,"answer":60,"author":5,"avatar":5,"time":5},"How does White House pressure on FDA decisions affect seller confidence?","The Moderna vaccine reversal (rejected then approved after White House pressure) demonstrates that FDA decisions may be influenced by political factors rather than purely scientific review. This creates unpredictability for sellers who cannot reliably forecast approval outcomes. Biotech suppliers and health product manufacturers face investment uncertainty, potentially affecting product availability and pricing. Sellers should diversify suppliers and avoid over-dependence on single-source manufacturers. Monitor political developments affecting FDA leadership, as changes in administration or health policy could trigger additional regulatory reversals affecting product categories.",{"title":62,"answer":63,"author":5,"avatar":5,"time":5},"What compliance documentation should sellers maintain during FDA regulatory transitions?","Sellers should maintain comprehensive documentation including: (1) Clinical studies or substantiation for all health claims; (2) FDA guidance references supporting current claims (dated and versioned); (3) Ingredient sourcing and supplier certifications; (4) Product testing results and safety data; (5) Marketing claim history and revisions. This documentation protects sellers if FDA guidance shifts and claims require revision. Maintain records for minimum 3 years. During leadership transitions, FDA enforcement priorities may shift; sellers with strong documentation can demonstrate good-faith compliance efforts. Use Amazon Seller Central compliance tools and eBay seller documentation features to track claim changes.",{"title":65,"answer":66,"author":5,"avatar":5,"time":5},"How should sellers prepare for continued FDA regulatory uncertainty through 2026?","Sellers should implement three immediate actions: (1) Audit all health claims in product listings against current FDA guidance by April 2026; (2) Establish relationships with regulatory compliance consultants to monitor FDA announcements; (3) Build 30-60 day buffer into product development cycles to accommodate potential claim revisions. Strategically, consider diversifying into product categories with lower regulatory risk (general wellness, non-health-claim products). Monitor FDA.gov and subscribe to regulatory update services. Budget 5-10% of marketing spend for potential claim adjustments and compliance updates through end of 2026.",{"title":68,"answer":69,"author":5,"avatar":5,"time":5},"What is the financial impact of FDA regulatory uncertainty on health product sellers?","Regulatory uncertainty creates three cost categories: (1) Compliance monitoring and legal review ($500-2,000/month for mid-size sellers); (2) Product reformulation and relabeling (5-15% of COGS if claims require revision); (3) Inventory risk (potential need to clear stock if claims become non-compliant). Sellers with 100+ SKUs in health categories should budget $1,000-5,000 monthly for regulatory monitoring. Larger sellers (10M+ annual revenue) may face $50K-200K in compliance costs if major claim restrictions occur. The pattern of leadership changes suggests this cost will persist through 2026.",{"title":71,"answer":72,"author":5,"avatar":5,"time":5},"How does FDA vaccine leadership instability affect health product sellers on Amazon and eBay?","FDA leadership changes directly impact health product sellers through unpredictable approval timelines and shifting compliance requirements. Dr. Prasad's departure (effective April 2026) represents the second major FDA vaccine chief departure in 12 months, creating institutional uncertainty. Sellers listing vitamins, supplements, immune support products, and wellness devices must monitor FDA guidance changes, as contradictory regulatory signals from leadership transitions can affect permissible health claims. Amazon and eBay health product categories require FDA-compliant claims; sellers should review product listings quarterly and maintain documentation of claim substantiation to prepare for potential regulatory shifts.",{"title":74,"answer":75,"author":5,"avatar":5,"time":5},"What specific product categories are most vulnerable to FDA regulatory changes?","Immune support supplements, vitamin D products, probiotics, flu prevention supplements, and general wellness formulations face the highest regulatory risk during FDA leadership transitions. The Moderna flu vaccine rejection (later reversed) signals heightened scrutiny of respiratory health claims. Sellers in these categories should expect potential claim restrictions or new warning label requirements. Supplement sellers should prioritize third-party testing and clinical substantiation for all health claims. Estimate 15-25% of current supplement listings may require claim revisions if FDA guidance shifts toward stricter interpretation of permissible health claims.",[77,82,86,90,94,98,102,105,109,113,117,121,124,127,131,135,139,142,146,150,153,157,160,164,167,170,174,177,181,185,188,192,195,199,202,205,208,211,215,219,222,225,228,232,236,240,244,247],{"id":78,"title":79,"source":80,"logo":17,"time":81},540643,"US FDA’s Vinay Prasad, Controversial CBER Director, Leaving In April","https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/us-fdas-vinay-prasad-controversial-cber-director-leaving-in-april-DJO7ACE73RCNTLZKQWCN2S26LM/","1D AGO",{"id":83,"title":84,"source":85,"logo":21,"time":81},542228,"Trump administration’s embattled FDA vaccine chief is leaving for the second time","https://apnews.com/article/vinay-prasad-fda-trump-vaccine-moderna-fired-bf56fe9852def8c9f1b9a648e5bb92df",{"id":87,"title":88,"source":89,"logo":14,"time":81},541678,"FDA Vaccine Chief Vinay Prasad to Leave the Agency in April","https://www.ntd.com/fda-vaccine-chief-vinay-prasad-to-leave-the-agency-in-april_1130524.html",{"id":91,"title":92,"source":93,"logo":46,"time":81},542227,"FDA Vaccine Chief Prasad To Exit Agency For 2nd Time","https://www.law360.com/health/articles/2450169/fda-vaccine-chief-prasad-to-exit-agency-for-2nd-time?about=health",{"id":95,"title":96,"source":97,"logo":48,"time":81},541679,"FDA vaccines chief Vinay Prasad to leave regulator in April","https://www.ksl.com/article/51458458/fda-vaccines-chief-vinay-prasad-to-leave-regulator-in-april",{"id":99,"title":100,"source":101,"logo":49,"time":81},540646,"Trump administration's embattled FDA vaccine chief is leaving for the second time","https://www.10tv.com/article/syndication/associatedpress/trump-administrations-embattled-fda-vaccine-chief-is-leaving-for-the-second-time/616-28b31a3a-ef3d-4491-a32a-6eb3ff98eb07",{"id":103,"title":100,"source":104,"logo":40,"time":81},542229,"https://www.newspressnow.com/news/regional_news/nebraska/trump-administrations-embattled-fda-vaccine-chief-is-leaving-for-the-second-time/article_2bbb8d9b-1dc0-5ede-b723-910582f8b953.html",{"id":106,"title":107,"source":108,"logo":5,"time":81},539834,"FDA vaccines chief who ran afoul of pharma to depart","https://www.politico.com/news/2026/03/06/fda-vaccines-chief-who-ran-afoul-of-pharma-to-depart-00817746",{"id":110,"title":111,"source":112,"logo":44,"time":81},540640,"Top FDA regulator to leave the agency","https://thehill.com/policy/healthcare/5772505-fda-vinay-prasad-departure/",{"id":114,"title":115,"source":116,"logo":42,"time":81},539810,"FDA vaccines chief Prasad to step down","https://sjvsun.com/u-s/fda-vaccines-chief-prasad-to-step-down/",{"id":118,"title":119,"source":120,"logo":28,"time":81},539832,"FDA vaccine chief to leave the agency for a second time","https://www.nbcnews.com/health/health-news/fda-vaccine-chief-leave-second-time-rcna262170",{"id":122,"title":92,"source":123,"logo":34,"time":81},540641,"https://www.law360.com/articles/2450169/fda-vaccine-chief-prasad-to-exit-agency-for-2nd-time",{"id":125,"title":100,"source":126,"logo":12,"time":81},542226,"https://www.kpbs.org/news/health/2026/03/06/trump-administrations-embattled-fda-vaccine-chief-is-leaving-for-the-second-time",{"id":128,"title":129,"source":130,"logo":32,"time":81},540642,"Trump Administration's Embattled FDA Vaccine Chief Is Leaving For The Second Time","https://www.huffpost.com/entry/fda-vaccine-chief_n_69ab68a7e4b03ae2f886ca1c",{"id":132,"title":133,"source":134,"logo":20,"time":81},542225,"Controversial FDA Vaccines Chief Vinay Prasad To Leave Agency In April - Moderna (NASDAQ:MRNA)","https://www.benzinga.com/news/fda/26/03/51114978/controversial-fda-vaccines-chief-vinay-prasad-to-leave-agency-in-april",{"id":136,"title":137,"source":138,"logo":45,"time":81},540629,"Cesspool of Chaos: Vinay Prasad Headed Out At Trump FDA","https://www.protectourcare.org/cesspool-of-chaos-vinay-prasad-headed-out-at-trump-fda/",{"id":140,"title":100,"source":141,"logo":15,"time":81},540548,"https://www.yahoo.com/news/articles/trump-administrations-embattled-fda-vaccine-230219148.html",{"id":143,"title":144,"source":145,"logo":18,"time":81},540647,"FDA Vaccine Chief Vinay Prasad Set to Leave Post Next Month","https://finance.yahoo.com/news/fda-vaccine-chief-vinay-prasad-225628622.html",{"id":147,"title":148,"source":149,"logo":26,"time":81},540628,"FDA vaccine chief Dr. Vinay Prasad to leave agency next month","https://abcnews.com/Politics/fda-vaccine-chief-dr-vinay-prasad-leave-agency/story?id=130842370",{"id":151,"title":100,"source":152,"logo":35,"time":81},541680,"http://www.wyff4.com/article/fda-vaccine-chief-leaving-second-time/70646899",{"id":154,"title":155,"source":156,"logo":31,"time":81},539806,"FDA Vaccine Director Dr. Vinay Prasad Steps Down Again After Controversies","https://www.finedayradio.com/news/tv-delmarva-channel-33/fda-vaccine-director-dr-vinay-prasad-steps-down-again-after-controversies/",{"id":158,"title":100,"source":159,"logo":23,"time":81},541681,"https://www.koat.com/article/fda-vaccine-chief-leaving-second-time/70646899",{"id":161,"title":162,"source":163,"logo":10,"time":81},539803,"FDA’s Prasad To Depart FDA Following Tumultuous Term as CBER Chief","https://www.biospace.com/fda/fdas-prasad-to-depart-fda-following-tumultuous-term-as-cber-chief",{"id":165,"title":111,"source":166,"logo":30,"time":81},541682,"https://www.yahoo.com/news/articles/top-fda-regulator-leave-agency-022319486.html",{"id":168,"title":100,"source":169,"logo":11,"time":81},542233,"https://www.ksat.com/news/politics/2026/03/06/trump-administrations-embattled-fda-vaccine-chief-is-leaving-for-the-second-time/",{"id":171,"title":172,"source":173,"logo":19,"time":81},542299,"Opinion | Vinay Prasad Is Out at the FDA—Again","https://www.wsj.com/opinion/fda-marty-makary-vinay-prasad-uniqure-accelerated-approvals-ab0548ff?gaa_at=eafs&gaa_n=AWEtsqd1NwiImVGM0unalxJp9Jx735dTWOLCRl6qmrWFFbWjoCcBd5DoICWM&gaa_ts=69ac1811&gaa_sig=qjvCaTiUQzTe1xJzywlRVQ0qPVxG8dz2uXxlvKdV6mhevqbqN7TPwh0CRHdcJEhg27Ed-ijqe3FgJSCVdj6FjA%3D%3D",{"id":175,"title":100,"source":176,"logo":29,"time":81},542232,"https://www.ottumwacourier.com/news/national_news/trump-administrations-embattled-fda-vaccine-chief-is-leaving-for-the-second-time/article_5841787f-798a-5326-8082-c79fda7074f2.html",{"id":178,"title":179,"source":180,"logo":36,"time":81},539807,"FDA Vaccine Chief","https://www.timesargus.com/news/national/fda-vaccine-chief/image_3c3e2537-665a-5451-bd9c-abf7ddafc7cd.html",{"id":182,"title":183,"source":184,"logo":27,"time":81},540632,"Trump's controversial vaccine chief ousted","https://www.rawstory.com/dr-vinay-prasad-fda/",{"id":186,"title":100,"source":187,"logo":25,"time":81},539820,"https://www.sfgate.com/news/politics/article/trump-administration-s-embattled-fda-vaccine-21960117.php",{"id":189,"title":190,"source":191,"logo":5,"time":81},540633,"FDA vaccines chief Dr. Vinay Prasad to leave regulator in April","https://www.usatoday.com/story/news/politics/2026/03/06/fda-vaccines-chief-vinay-prasad-to-leave-in-april/89031060007/",{"id":193,"title":100,"source":194,"logo":23,"time":81},540634,"https://www.wmur.com/article/fda-vaccine-chief-leaving-second-time/70646899",{"id":196,"title":197,"source":198,"logo":38,"time":81},539840,"FDA's top vaccine regulator to leave in April","https://www.axios.com/2026/03/06/fda-vaccine-vinay-prasad-hhs",{"id":200,"title":100,"source":201,"logo":35,"time":81},540635,"http://www.wlwt.com/article/fda-vaccine-chief-leaving-second-time/70646899",{"id":203,"title":100,"source":204,"logo":24,"time":81},539823,"https://wacotrib.com/ap/washington/article_db5fce7f-1cef-5fe4-95c8-578f75ff1389.html",{"id":206,"title":100,"source":207,"logo":43,"time":81},539824,"https://www.thederrick.com/ap/washington/trump-administrations-embattled-fda-vaccine-chief-is-leaving-for-the-second-time/article_5621f592-e299-5116-b6dc-500cac5ce8a9.html",{"id":209,"title":100,"source":210,"logo":39,"time":81},539821,"https://www.wral.com/news/ap/bf56f-trump-administrations-embattled-fda-vaccine-chief-is-leaving-for-the-second-time/",{"id":212,"title":213,"source":214,"logo":41,"time":81},539964,"Trump administration’s embattled FDA vaccine chief ousted for the second time","https://www.theguardian.com/us-news/2026/mar/06/fda-vaccine-chief-ousted-vinay-prasad",{"id":216,"title":217,"source":218,"logo":37,"time":81},540630,"Vinay Prasad to leave the FDA, again","https://firstwordpharma.com/story/7129480",{"id":220,"title":100,"source":221,"logo":16,"time":81},540739,"https://www.npr.org/2026/03/06/nx-s1-5740596/trump-administrations-embattled-fda-vaccine-chief-is-leaving-for-the-second-time",{"id":223,"title":100,"source":224,"logo":35,"time":81},540636,"https://www.wgal.com/article/fda-vaccine-chief-leaving-second-time/70646899",{"id":226,"title":100,"source":227,"logo":35,"time":81},540637,"https://www.ksbw.com/article/fda-vaccine-chief-leaving-second-time/70646899",{"id":229,"title":230,"source":231,"logo":5,"time":81},539838,"Controversial top vaccine regulator to depart FDA","https://www.washingtonpost.com/health/2026/03/06/fda-vaccine-regulator-prasad-out/",{"id":233,"title":234,"source":235,"logo":47,"time":81},539814,"Trump Live Updates: Vaccine Chief to Leave F.D.A., Kristi Noem Perjury Investigation and More News","https://www.nytimes.com/live/2026/03/06/us/trump-news-updates",{"id":237,"title":238,"source":239,"logo":22,"time":81},539836,"FDA's Controversial Vaccine Chief Exits ... Again","https://www.medpagetoday.com/washington-watch/fdageneral/120210",{"id":241,"title":242,"source":243,"logo":13,"time":81},539837,"FDA's Vinay Prasad to Depart as CBER Head for Second Time","https://www.contagionlive.com/view/fda-vinay-prasad-depart-cber-head-second-time",{"id":245,"title":172,"source":246,"logo":19,"time":81},541595,"https://www.wsj.com/opinion/fda-marty-makary-vinay-prasad-uniqure-accelerated-approvals-ab0548ff?gaa_at=eafs&gaa_n=AWEtsqc-MYmqSmSeJ9uxd6GXPXSOZEii50tD_KUuCCFPWNXbTHH6CBDVmtzE&gaa_ts=69abdfd3&gaa_sig=hQ-u3FiHT6xbsT-MiDXcEZCsaYkVrhJXr-l8nbAo2s2htaKRfRawPueK6iobDJGZur9KhK9IrhRqVtCCvD2JzA%3D%3D",{"id":248,"title":249,"source":250,"logo":33,"time":81},539819,"Controversial FDA vaccine chief to leave agency","https://www.washingtonexaminer.com/news/4484165/controversial-fda-vaccine-chief-vinay-prasad-leave-agency/","#449714ff","#4497144d",1772980265236]